Hematopoietic stem cells for systemic lupus erythematosus

The aim of this study is to assess the safety and feasibility of autologous peripheral hematopoietic stem cell transplantation in patients with systemic lupus erythematosus, following patient conditioning with high-dose cyclophosphamide and anti-thymocyte globulin. The treatment resulted in amelioration of disease symptoms, improvement in serologic markers, and either stabilization or reversal of organ dysfunction.